Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27815181 | 0.83 | MAPT (0.67) | CES1MEN1KMT2APOLBCA1 | |
| SCHEMBL28723007 | 0.83 | MEN1 (0.82) | CES1MEN1KMT2APOLBCA1 | |
| SCHEMBL296991 | 0.82 | MEN1 (0.68) | CES1MEN1KMT2APOLBCA1 | |
| SCHEMBL223451 | 0.80 | MAPT (0.63) | CES1MEN1KMT2APOLBCA1 | |
| SCHEMBL165760 | 0.80 | TSHR (0.62) | CES1MEN1KMT2APOLBCA1 | |
| SCHEMBL6973230 | 0.80 | CES1 (0.61) | CES1MEN1KMT2APOLBCA1 | |
| Potassium Ion SCHEMBL10903588 | 0.80 | CES1 (0.61) | CES1MEN1KMT2APOLBCA1 | |
| SCHEMBL9848997 | 0.80 | ALDH1A1 (0.62) | CES1MEN1KMT2APOLBCA1 | |
| SCHEMBL8866584 | 0.80 | CES1 (0.61) | CES1MEN1KMT2APOLBCA1 | |
| SCHEMBL23898948 | 0.78 | KMT2A (0.83) | MEN1KMT2APOLBALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104710367-A | Method for synthesizing enzalutamide | UNIV CHINA PHARMA | 2015-06-17 | — | — | CN | claimed |
| CN-104003939-A | Diaryl substituted glycolythiourea compounds as well as preparation method and application thereof | UNIV SHANDONG | 2014-08-27 | — | — | CN | claimed |
| CN-110003114-A | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-07-12 | — | — | CN | disclosed |
| CN-105037273-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2019-04-19 | — | — | CN | disclosed |
| CN-109422725-A | Drugs for prostate cancer | 北京美倍他药物研究有限公司 | 2019-03-05 | — | — | CN | disclosed |
| CN-105037273-A | Diaryl hydantoin compound | UNIV CALIFORNIA | 2015-11-11 | — | — | CN | disclosed |
| CN-104710367-A | Method for synthesizing enzalutamide | UNIV CHINA PHARMA | 2015-06-17 | — | — | CN | disclosed |
| CN-104341352-A | Diaryl hydantoin compound as androgen receptor antagonist and applications of diaryl hydantoin compound | NANJING HENGJIE BIOTECHNOLOGY CO LTD | 2015-02-11 | — | — | CN | disclosed |
| CN-102755318-B | Hyperproliferative disorders with diarylhydantoin compounds | UNIV CALIFORNIA | 2014-09-10 | — | — | CN | disclosed |
| CN-104003939-A | Diaryl substituted glycolythiourea compounds as well as preparation method and application thereof | UNIV SHANDONG | 2014-08-27 | — | — | CN | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | CES1 2154/4885MEN1 734/4885KMT2A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.